Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US6294441000
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: -
NRXP
NRx Pharmaceuticals, Inc.
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
NRx Pharmaceuticals, Inc.
ISIN
US6294441000
TICKER
NRXP
MIC
XNAS
REUTERS
NRXP.OQ
BLOOMBERG
NRXP US
Mi., 26.01.2022       NRx Pharmaceuticals
US6294441000

Los Angeles, California--(Newsfile Corp. - January 26, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NRx Pharmaceuticals, Inc. ("NRx" or "the Company") (NASDAQ: NRXP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 1...
Zur Nachricht
NRx Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mi., 26.01.2022       NRx Pharmaceuticals
US6294441000

New York, New York--(Newsfile Corp. - January 26, 2022) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ: NRXP) (NASDAQ: NRXPW) on behalf of purchasers of NRx securities between June 1, 2021 and November 4, 2021, both dates inclu...
Zur Nachricht
NRx Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Di., 25.01.2022       NRx Pharmaceuticals
US6294441000

New York, New York--(Newsfile Corp. - January 25, 2022) - Pomerantz LLP announces that a class action lawsuit has been filed against NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ: NRXP) (NASDAQ: NRXPW) and certain of its officers. The class action, filed in the United States District Court for the District of Delaware, and docketed...
Zur Nachricht
NRx Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Di., 25.01.2022       NRx Pharmaceuticals
US6294441000

Los Angeles, California--(Newsfile Corp. - January 25, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NRx Pharmaceuticals, Inc. ("NRx" or "the Company") (NASDAQ: NRXP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 1...
Zur Nachricht
NRx Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mo., 24.01.2022       NRx Pharmaceuticals
US6294441000

Los Angeles, California--(Newsfile Corp. - January 24, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NRx Pharmaceuticals, Inc. ("NRx" or "the Company") (NASDAQ: NRXP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 1...
Zur Nachricht
NRx Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Fr., 21.01.2022       NRx Pharmaceuticals
US6294441000

Los Angeles, California--(Newsfile Corp. - January 21, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NRx Pharmaceuticals, Inc. ("NRx" or "the Company") (NASDAQ: NRXP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 1...
Zur Nachricht
NRx Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Fr., 21.01.2022       NRx Pharmaceuticals
US6294441000

San Diego, California--(Newsfile Corp. - January 20, 2022) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) (NASDAQ: NRXPW) securities between June 1, 2021 and November 4, 2021, inclusive (the "Class Period") have until March 21, 2022 to seek appointment as lead plaintiff i...
Zur Nachricht
NRx Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 20.01.2022       NRx Pharmaceuticals
US6294441000

Los Angeles, California--(Newsfile Corp. - January 20, 2022) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NRx Pharmaceuticals, Inc. ("NRx" or "the Company") (NASDAQ: NRXP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 1...
Zur Nachricht
NRx Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Do., 20.01.2022       NRx Pharmaceuticals
US6294441000

New York, New York--(Newsfile Corp. - January 19, 2022) - Pomerantz LLP announces that a class action lawsuit has been filed against NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ: NRXP; NRXPW) and certain of its officers. The class action, filed in the United States District Court for the District of Delaware, and docketed under 22-c...
Zur Nachricht
NRx Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Mi., 19.01.2022       NRx Pharmaceuticals
US6294441000

New York, New York--(Newsfile Corp. - January 19, 2022) - Gainey McKenna & Egleston announces that a class action lawsuit has been filed against NRx Pharmaceuticals, Inc. ("NRx") (NASDAQ: NRXP) (NASDAQ: NRXPW) in the United States District Court for the District of Delaware on behalf of investors who purchased NRx's common stock between June 1,...
Zur Nachricht
NRx Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 08.11.2021       NRx Pharmaceuticals
US6294441000

New York, New York--(Newsfile Corp. - November 8, 2021) - Pomerantz LLP is investigating claims on behalf of investors of NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ: NRXP). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether NRx and certa...
Zur Nachricht
NRx Pharmaceuticals
Charts & Research Termsheets Terminal
Permalink